Isis Pharmaceuticals SVP Brett Monia Sells 68,281 Shares (ISIS)
Isis Pharmaceuticals (NASDAQ:ISIS) SVP Brett Monia sold 68,281 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $34.21, for a total value of $2,335,893.01. Following the transaction, the senior vice president now directly owns 769 shares in the company, valued at approximately $26,307. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
ISIS has been the subject of a number of recent research reports. Analysts at Goldman Sachs Group Inc. reiterated a “hold” rating on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note to investors on Monday. They now have a $26.00 price target on the stock. Separately, analysts at Needham & Company raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) to $46.00 in a research note to investors on Monday. They now have a “positive” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $23.00 to $27.00 in a research note to investors on Tuesday, September 10th. They now have a “hold” rating on the stock.
Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. Isis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $30.20.
Isis Pharmaceuticals (NASDAQ:ISIS) traded up 6.71% during mid-day trading on Monday, hitting $38.48. The stock had a trading volume of 4,140,218 shares. Isis Pharmaceuticals has a 52 week low of $7.56 and a 52 week high of $39.83. The stock has a 50-day moving average of $28.60 and a 200-day moving average of $24.24. The company’s market cap is $4.437 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last announced its earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter last year, the company posted ($0.01) earnings per share. Isis Pharmaceuticals’s revenue was down 19.5% compared to the same quarter last year. On average, analysts predict that Isis Pharmaceuticals will post $-0.56 earnings per share for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.